

DR. ANN de WEES ALLEN®
NUTRITIONAL NEUROSCIENCE
CHIEF OF BIOMEDICAL RESEARCH
CHIEF SCIENCE OFFICER

GLYCEMIC RESEARCH INSTITUTE®
GLYCEMIC.COM



DIRECTOR OF IIRB BOARD APPROVED
HUMAN IN VIVO CLINICAL TRIALS
GLYCEMIC INDEX & LOAD
PIONEER IN L-ARGININE RESEARCH SINCE 1983:
PATENT AWARDED: PRESENTED AT
THE UNITED NATIONS GENERAL ASSEMBLY
GUT-BRAIN AXIS: OBESITY & DIABETES
SPORT SCIENCE RESEARCH & DEVELOPMENT

ASSOCIATION OF CLINICAL RESEARCH
PROFESSIONALS: ACRP MEMBER for 19 YEARS:
2005 TO CURRENT 2024

**GLYCEMIC RESEARCH INSTITUTE®
GLYCEMIC.COM
CAPITOL HILL-WASHINGTON, D.C.**

Background Clinical Research Projects

Glycoside Metabolic Research (Monk Fruit/Stevia)

Glycemic Index & Load

**Obesity & Diabetes: Board Approved Clinical Trials
in Adults & Children**

**Sickle Cell & Thalassemia: Dr. Ann de Wees Allen's
Presentation by invitation to lecture at the at the *United
Nations General Assembly*. Topic: Dr. Allen's L-
Arginine's Patent for Modulation of Sickle Cell Anemia
in which her research & Patent acts as a Modulatory
Neurotransmitter which is transmitted intracellularly
unique because the formula/Patent does not require a
receptor (unique among neurotransmitters) in which
Nitric Oxide is produced by said formula/Patent acting
as a signaling molecule in the central and peripheral
nervous systems, playing a role in various neurological
functions and processes; which is uniquely notable for
the ability to diffuse freely through cell membranes,
allowing for retrograde signaling.**

United Nations General Assembly, New York, Dr. Allen's 5-year research project on L-Arginine with joint partner Researchers: *John's Hopkins Dept. of Genetics* & Dr. Randall Maxey, MD, PhD, President of the *National Medical Association*

Microgravity in Space Flight – NASA – Top 5 Winner: Dr. Allen Patent for the Mitigation of the Side Effects of Microgravity during Space Flight in Astronauts

Sport Performance Beverages: Research & Development: Professional Sport Performance: Metabolic Fuel in Sports Science: NSF Approved

- **RESEARCH & DEVELOPMENT OF BRAIN-FRIENDLY FUEL & SPORT-FUEL IN THE FIELD OF BRAIN ENERGETICS (based on Board Approved Human In Vivo Clinical Trials)**

Gut-Brain Axis: Neural Coding
Director: Nutritional Neuroscience in Coding Foods & Beverages

METABOLIC GPS SYSTEMS IN THE GUT-BRAIN AXIS: DEVELOPING ALTERNATIVES TO HIGH GLYCEMIC SUGARS, SWEETENERS, NON-METABOLIC & ARTIFICIAL SWEETENERS:
PLANT-BASED (GRAS) BIOMOLECULES AS ZWITTERIONS; CROSSING THE BLOOD-BRAIN BARRIER (BBB) IN HUMANS:

CORE VECTOR COMPOUNDS; INCLUDING L-ARGININE & SWEET-FLAVOR SYSTEMS (Dr. Allen Patent Received)

RESEARCH DIAMETERS & QUANTIFICATIONS:

- **IRBB BOARD APPROVED HUMAN IN VIVO CLINICAL TRIALS**
- **LC-MS; Liquid Chromatography Mass Spectrophotometer; Design & Identification of Viable Plant-Based Biomolecules: *TIME OF FLIGHT* LCMS: Research conducted by independent laboratory for Dr. Allen Core Vector Compounds**
- **LC-MS IDENTIFICATION & UTILIZATION OF BRAIN & BLOOD-SUGAR APPROPRIATE SUGARS, SWEETENERS, GLYCOSIDES, AND PLANT METABOLICS IN THE DESIGN OF BLOOD-SUGAR, DIABETIC, OBESITY, AND KID-FRIENDLY NATURAL SWEET-SYSTEMS FOR FOODS & BEVERAGES (with Clinical Research)**

AWARDS, PATENTS, TECHNOLOGY

NEWSWEEK MAGAZINE NEWSWEEK MEDIA

Dr. Ann de Wees Allen® named as one of the “TOP 10 EXPERTS in the World”

SCIENTIST GENERATES OVER \$ 1 BILLION DOLLARS IN PATENTS & TECHNOLOGY

**FIRST GLYCEMIC PATENT EVER AWARDED
WORLDWIDE**

**1st PATENT EVER AWARDED ON GLYCEMIC
INDEX: PIONEER OF THE GLYCEMIC INDEX**

WHO'S WHO OF AMERICAN INVENTORS:

PATENTS ISSUED: Allen, Ann de Wees

DATA BACKED BY IRBB CLINICAL TRIALS

UNITED STATES PATENT OFFICE: USPTO

- **LOW GLYCEMIC BEVERAGES, INCLUDING ENERGY DRINKS, COFFEE, TEAS, WATER, OR ANY OTHER ORALLY CONSUMED LIQUID; DOWNREGULATION OF ADIPOSE TISSUE FAT-STORAGE IN HUMAN FAT CELLS VIA LPL AND FTO OBESITY GENE; ADIPOSE TISSUE FAT-BURNING THERMODYNAMICS; BLOOD GLUCOSE CONTROL IN BEVERAGE TECHNOLOGY & SWEETENING-SYSTEMS WITH DELIBERATE BRIX LEVEL TECHNOLOGY**
- **LOW GLYCEMIC TECHNOLOGY IN WEIGHT MANAGEMENT, TYPE 2 DIABETES, & SPORT DRINKS**
- **LOW GLYCEMIC KEY CODED BIO-MOLECULES IN FOODS & BEVERAGE FORMULAS & DESIGN**
- **METABOLIC THERMODYNAMICS: Dr. Allen Patent FUEL PARTITIONING IN THE PRODUCTION OF ATP BRAIN FUEL VIA THE GUT-BRAIN AXIS (GBA); IN VIVO BRAIN UPTAKE OF LOW GLYCEMIC ENERGY/FUEL SYSTEMS TRIGGERED AT THE CEPHALIC PHASE OF THE GBA & TRANSPORTED VIA THE NEURAL GLUT 1 PATHWAY; NEURAL TRANSPORTER SYSTEMS IN THE GBA; NEURAL**

DETERMINATION OF MOLECULAR AND MOLAR MASS TRANSPORTER BIO-MOLECULES IN THE GBA, WHEREIN SAID MOLECULES DO NOT STIMULATE INSULIN-OVER-ELEVATION IN BLOOD GLUCOSE

- **GUT-BRAIN AXIS (GBA) ORAL RECEPTOR RESPONSE UTILIZING PLANT-BASED MOLECULAR TRANSPORT SYSTEMS IN THE BLOOD-BRAIN BARRIER (BBB) FOR THE DELIVERY OF MEMBRANE-IMPERMEABLE BIO-COMPOUNDS AS ANALOGS THAT CROSS THE BBB VIA SAID TRANSPORTERS; DESIGN & PRODUCTION OF BIO-MOLECULES THAT TRANSPORT GBA NEURAL MESSAGES & BRAIN-FUEL FROM THE *MOUTH-TO-THE-BRAIN* (Demonstrated by Board Approved IRBB Human In Vivo Clinical Trials)**
- **NUTRITIONAL NEUROSCIENCE; CROSSING THE BLOOD-BRAIN BARRIER (BBB) TO ELICIT THE PRODUCTION OF GROWTH HORMONE (GH), NITRITIC OXIDE, & ANTI-AGING IN HUMANS; UTILIZATION OF L-ARGININE AS A ZWITTERION IN PHARMACEUTICAL AGENTS & IN SICKLE CELL DISEASE (human subjects data provided to the USPTO Patent Office (1 \$ Billion Dollars generated by this patent globally))**

USPTO AWARDED REGISTERED TRADEMARKS

Allen, Ann de Wees: 52 Trademarks including *Switch the Brain-Switch the Game*.

WILLIAM SHATNER (Captain James T. Kirk, STAR TREK) Conducts 1-Hour Interview with Top Research Scientist Dr. Ann de Wees Allen®

William Shatner names Dr. Ann de Wees Allen® as one of “America’s Finest Entrepreneurs”

SHOW TOPIC: *America’s Finest Entrepreneurs*

William Shatner TV "Moving America Forward" hosted by William Shatner Media Production

CLINICAL RESEARCH SCIENTIST

COMBINATORIAL CHEMISTRY: EPA CHEMIST

DR. ALLENs RESEARCH ON POLYCHLORINATED

BYPHENOLS (PCB’S) for the ENVIRONMENTAL

PROTECTION AGENCY DETERMINED THE

CARCINOGENIC PROPERTIES OF PCB’S

PUBLISHED ON THE FRONT PAGE OF THE WALL STREET JOURNAL: \$300. Million dollars generated in 1st year of Patent Awarded. Dr. Ann de Wees Allen’s Patented products went on to generate over A \$Billion Dollars for top Global Nutraceutical Companies.

DR. ANN DE WEES ALLEN® AWARD FOR:

“BREAKTHROUGH PRODUCT OF THE YEAR” by Success magazine for her Patent on Metabolic Thermodynamics

GLYCOSIDE RESEARCHER

FIRST SCIENTIST TO BRING MONK FRUIT INTO THE UNITED STATES TO CONDUCT GLYCOSIDE CLINICAL TRIALS in HUMANS & DETERMINE GLYCOSIDE METABOLIC RESPONSE; UTILIZATION OF NATURAL PLANT BASED TECHNOLOGY IN NATURAL LOW GLYCEMIC SWEETENERS, FOODS & BEVERAGES, NUTRACEUTICALS & PHARMACEUTICALS

PATENT RECEIVED: NEURAL TRANSPORT OF METABOLIC AGENTS ENTERING THE BLOOD-BRAIN BARRIER ACTIVATING THE HYPOTHALAMIC-PITUITARY AXIS (HPA)

NASA: Mitigation of the Side Effects of Microgravity in Astronauts During Space Flight; Research by Dr Ann de Wees Allen® on L-Arginine & Microgravity

Who's Who in *Diabetes Education and Research* by the *American Diabetes Association* & member of the *American Diabetes Association Council on Nutritional Science & Metabolism*

Global Medical Lectures Worldwide-in Asia for 5½ Years (Thalassemia – Sickle Cell): Tokyo Convention Center; Singapore, Hong Kong, Malaysia, Thailand

PATENTS IN BEVERAGE TECHNOLOGY: CODING OF THE GUT-BRAIN AXIS IN HUMANS-DIRECTIONAL BIO-CODING of FOODS & BEVERAGES VIA ORAL INGESTION OF CODED CORE VECTOR COMPOUNDS: Downregulating Adipose Tissue Fat Storage via Lipoprotein Lipase (LPL) via Coffee, Tea, including any beverage. Received the 1stL-Arginine Patent for Reinstatement of Hypothalamus/Pituitary Generated Growth Hormone (GH) via the Blood-Brain Barrier (BBB)

NEWS: BOLD SCIENTIST CORRECTS

DISCOVER MAGAZINE! Known in the industry for her bold stance of setting high standards in scientific accuracy, Dr. Ann de Wees Allen[®] went so far as to correct *Discover* magazine, whose educational publication is considered the gold standard in science. Her statement on quaternary saturated amines prompted a correction by *Discover*. As a result of Dr. Allen's long-term research and patent on the amino acid L-arginine, the medical and scientific community referred to her as the *Leader in L-Arginine Biochemistry*, and the *Queen of Arginine*. The *Biology Dictionary* selected Dr. Allen's definition of L-arginine as their standard. When Dr. Allen was asked by the media how she was able to stay on the leading edge of *future-science*, she replied: "Part science, part skill, and part intuition. Speculating on nonlinear images allows me to think much more quickly and multi-dimensionally. Albert Einstein used this method and was able to develop his theory of relativity due to his ability to make intuitive leaps. Intuitive leaps allow me to ignore conventional science and make theoretical bonds with metabolic concepts. The key then, is to scientifically prove these concepts."

GERALDO RIVERA TV SHOW FEATURING DR. ANN DE WEES ALLEN, TOP SPORTS PERFORMANCE RESEARCHER:

Dr. Allen's sport performance clients are considered the best athletes in the world, including the *World Powerlifting Association*, *Mr. Universe* (Ron Coleman), *Ms. Galaxy* (Brandi carrier), Olympic athletes, and numerous other athletes who use her patented L-Arginine products and Protein drinks, designed specifically for powerlifters, and her "*Zero-Defect Machine*" Low Glycemic food programs. As proof that her programs work, one of the female powerlifters stated that Dr. Allen's products and programs allowed her to win World Titles as the "Strongest Woman in the World" with a record of 650-pound squats. Dr. Allen's bodybuilding clients consume huge amounts of food including her patented Low Glycemic Protein Drinks, while holding 6 percent body fat, a feat once considered impossible. Arnold Schwarzenegger invited Dr. Allen to lecture with him at the Arnold Classic to present her research in sport science, and to bring some of the top athletes with her, which she paraded across the stage. The Geraldo Rivera show featured Dr. Ann de Wees Allen and Lou Ferrigno, and Dr. Allen had no problem arguing with Ferrigno about growth hormone and L-Arginine. This show was named one of the top favorites.

DR. ANN DE WEES ALLEN CLIENTS

CONSULTANT TO PROFESSIONAL ATHLETES

Consultant to World Powerlifting Association, Mr. Universe, Ms. Galaxy, Arnold Schwarzenegger Classic, and world-class athletes. Designed & Formulated line of Sport Products: GH, Nitric Oxide, Protein Drinks, Performance Drinks (Patents Received)

CLEAR CHANNEL SPORTS RADIO: Dr. Ann de Wees Allen; Top Guest Expert in Sport Nutrition; Consultant to Tampa Bay Bucs

INDIAN NATIONAL CRICKET TEAM

YUVRAJ SINGH: Dr. Ann de Wees Allen® designed the high-performance Cricket Drink for maximum performance for the India National Cricket Team. Yuvraj Singh stated “I love Dr. Allen’s Cricket drink and use it in tournaments!” Yuvraj won 7 Player of the Series awards in ODI cricket, which is joint 3rd highest by an Indian. Yuvraj was conferred with the Arjuna Award, India's second highest sporting award by the Government of India, and was awarded the Padma Shri, India’s fourth highest honor, and was awarded the *FICCI Most Inspiring Sportsperson of the Year Award*.

JORDAN ROMERO: Dr. Allen formulated and Patented an L-Arginine Nitric Oxide formula for *World Record Holder in Mountain Climbing*, Jordan Romero, named the *Youngest Person in the World to climb Mt. Everest at age 13.*

INDYCAR CHAMPION MICHAEL ANDRETTI

Dr. Allen designed the Performance Drink Products for her client Michael Andretti; four-time *IndyCar champion and Formula One champion*


BRUCE SPRINGSTEEN

Dr. Allen designed the Energy Drink and Nutraceutical Products used by Bruce Springsteen onstage. Dr. Allen was a good friend of Springsteen's manager of 30-years, Terry Magovern, and Springsteen adopted the brother and sister of Dr. Allen's dog, Lady Sierra the 6th, German Shepherd Guard Dogs from the Applejack Academy.

[WIKIPEDIA.COM: Magovern, Terry & Bruce Springsteen. Frank Terry Magovern was a longtime assistant to Bruce Springsteen. After several years working in Jersey shore bars, Mr. Magovern began running Big Man's West, a Red Bank nightclub owned by Springsteen's saxophonist, Clarence Clemons. After the club closed a few years later, Mr. Magovern continued working for Clemons and in 1987 joined Springsteen and The E Street Band on their Tunnel of Love Express Tour. The concerts had a carnival theme, and, as each musician walked onto the stage, he handed a ticket to Mr. Magovern, who was sitting in a booth. Mr. Magovern served as Springsteen's personal assistant, and was credited with research on Springsteen's 1995 album, "The Ghost of Tom Joad," and was identified as Springsteen's "dedicated sidekick" on 2002's "The Rising".



UNITED NATIONS GENERAL ASSEMBLY World Sickle Cell Day – New York



Every year on June 19, the global sickle cell community unites to celebrate World Sickle Cell Day. For the sickle cell community, this day holds much significance. Also known as World Sickle Cell Awareness Day, this day is observed internationally to increase much-needed education and awareness of a disease that affects millions of people around the globe.

Origin and History

In 2006, the World Health Organization (WHO) recognized sickle cell disease (SCD) as a global health problem. Just one year earlier, the African Union and the United Nations Educational, Scientific, and Cultural Organization (UNESCO) had also recognized the disease as a global health problem, thanks to the advocacy of the Sickle Cell Disease International Organization (SCDIO), the support of the Republic of Congo and the Republic of Senegal, and the commitment in the scientific world. Their efforts brought to light how SCD was and is a heritable blood disorder with devastating effects.

In response, in 2008, the United Nations (UN) General Assembly created a resolution that formally recognized SCD as a public health problem. They declared SCD as “one of the most lethal genetic disorders” and “one of the world’s foremost genetic diseases.” The UN’s resolution served to increase the public’s awareness of SCD and its cure at a national and international level. The resolution was also created to improve the quality of life for patients with SCD worldwide and to observe June 19 as World Sickle Cell Day to continue raising awareness.

June 19, 2009 was the first date that World Sickle Cell Day was celebrated.



United Nations



Madame Antoinette Sassou Nguesso, First Lady of the Republic of Congo, and Madame Viviane Wade, First Lady of Senegal, joined forces to help establish a centre in Brazzaville, the Congolese capital, to study the disease, raise awareness, and bring scientists and medical professionals together to discuss prevention, care, and treatment. Howard University President Wayne A. I. Frederick pledged to develop and strengthen collaborations between the Howard Center for Sickle Cell Disease and the newly established National Sickle Cell Disease Center of Brazzaville, Congo. Madame Sassou Nguesso's endeavors with UNESCO, as President of the Congo Assistance Foundation, and as a sponsor of SCDIO in advocacy of raising the awareness of SCD in the Congo and globally have continued to advance the collective work of OILD. She received the WHO Director-General's Health Leaders Recognition to celebrate her contribution to the control of sickle cell anemia.

UNITED NATIONS GENERAL ASSEMBLY World Sickle Cell Day



RESEARCHERS – SPEAKERS AT THE UNITED NATIONS WORLD SICKLE CELL DAY

ALL NATIONS OF THE WORLD THAT ARE MEMBERS OF THE UNITED NATIONS WERE REPRESENTED AT THE WORLD SICKLE CELL DAY JUNE 19TH 2009. THESE INCLUDE:

NIGERIAN MEMBERS OF THE SICKLE CELL FOUNDATION OF NIGERIA: HOPE ALIVE SICKLE CELL ASSOCIATION OF ABEOKUTA, OGUN STATE

PERMANENT MEMBER OF THE REPUBLIC OF CONGO TO THE UNITED NATIONS (NEW YORK)

SECRETARY GENERAL OF THE UNITED NATIONS
PRESIDENT OF THE U.N. GENERAL ASSEMBLY
WHO & UNICEF - PRESIDENT OF OILD
FIRST LADY OF THE CONGO

RESEARCHERS & PROFESSORS PRESENTING:
FRANCE, INDIA, BRAZIL, U.S., CONGO, AFRICAN NATIONS,
SICKLE CELL & THALASSEMIA PATIENTS NETWORK,
SENEGAL, FIRST LADIES & MINISTERS OF AFRICAN
COUNTRIWORLD HEALTH ORGANIZATION, RESEARCH
SCIENTISTS FROM AROUND THE WORLD

ROUND TABLE MODERATORS:
DOCTOR LEON TSHILOLO (CONGO RDC)
TERESA GINGER DAVIS (USA)

SPEAKERS at the ROUND TABLE:
Representatives of the United Nations
First Ladies & Ministers of Health
Selected Research Scientists

JOHNS HOPKINS SCHOOL OF MEDICINE

June 19, 2009 marks the first annual World Sickle Cell Disease Day. Prompted by a United Nations resolution calling for the recognition of sickle cell anemia as a public health problem, World Sickle Cell Disease Day was established to promote awareness of this genetic disease that affects millions globally. Natalie Wood-Wright, associate director of public affairs for the Johns Hopkins Bloomberg School of Public Health discussed the importance of sickle cell disease awareness with Carlton Haywood associate faculty at the Johns Hopkins Berman Institute and assistant professor of medicine at the Johns Hopkins School of Medicine. He was diagnosed with sickle cell disease as a child and serves as an advocate for sickle cell education and policy change.

BY INVITATION OF TERESA G. DAVIS, UNITED NATIONS SICKLE DAY ROUND TABLE MODERATOR: DR. ANN DE WEES ALLEN, Medical & Clinical researcher with research partners esteemed DR. RANDALL MAXEY, MD, PhD, President of the National Medical Association & JOHNS HOPKINS genetic researchers. TOPIC: Dr. Allen's patent and long-term research on L-Arginine as a modulator of Sickle Cell & Thalassemia,

demonstrating that L-Arginine can exert beneficial effects in patients with Sickle Cell Disease in the crisis & steady-states of the disease. Dr. Allen's Patent on L-Arginine was designed and formulated to serve as a substrate for Nitric Oxide (NO) production with special utilization in mountain climbers at Mt. Kilimanjaro in Tanzania Africa (with a summit of 19,340 feet) who require higher levels than normal of Nitric Oxide. Her mountain climbing clients carried Dr. Allen's L-Arginine formula, designed to increase levels of NO metabolites, in their climb of the tallest summits in the world, making World Records. Additionally, L-Arginine (in a safe formula without L-Lysine) acts as a cardioprotective, hepatoprotective and immunomodulatory agent in humans. Dr. Allen's Patent on L-Arginine has already generated over \$1 Billion dollars globally. Dr. Allen's Patent on L-Arginine was the first to demonstrate that it crossed the blood-Brain Barrier (BBB) as a Zwitterion. Her Patented Core Vector Compound was used safely in thousands of humans over decades of use. Dr. Allen Core Vector Compound holds GRAS STATUS.

HOPE ALIVE SICKLE CELL ASSOCIATION OF ABEJO KUTA, OGUN STATE: A REGISTERED MEMBER OF THE SICKLE CELL FOUNDATION OF NIGERIA:

Researchers at Duke University and Howard Hughes Medical Center (HHMC) discovered one of the keys to the cause of pain in Sickle Cell disease. Their findings were reported in the *Jan 31, 2005 Proceedings of the National Academy of Sciences.*

The key was Nitric Oxide, a signaling molecule. Their research noted that the degree of Nitric Oxide deficiency directly correlated with symptom severity.

The Duke University/HHMC study found that the less Nitric Oxide produced, the greater the pain in Sickle Cell anemia patients.

In 1998 the Nobel Prize in Medicine was awarded to researchers in Nitric Oxide, which is produced by L-arginine in the body.

The world's leading researcher in L-Arginine is Dr. Ann de Wees Allen, who has spent decades researching the free-form amino acid L-Arginine, and her research has led to some breakthrough discoveries.

Columbia University refers to L-Arginine as the "Magic Bullet" for the cardiovascular system.

To be effective and safe, L-Arginine must utilize a low-glycemic method. Through much research and development, Dr. Allen determined that an L-Arginine molecule must be attached to a glycoside from plants which will allow L-Arginine to cross the proper barriers. Dr. Allen formulated a unique Low glycemic product called ProArgi-9 that was granted a Patent.

Under FDA and FTC regulations, and with the assistance of her attorney, Peter Barton Hutt, Director of the Food & Drug Association (FDA), and author of CFR 21 Guidelines, Dr. Allen was able to clinically prove that she could legally make of 15 claims, with the 14th claim as "Helps produce Nitric Oxide".

Prominent medical researchers, from Johns Hopkins and NIH, as well as the President of the *National Medical Association*, Dr. Randall Maxey, MD, PhD, and President of NMA Research Foundation for Ethnic-Related Diseases, with expert experience in genetic polymorphisms in African Americans, the researchers contacted Dr. Allen with the goal of forming a team specializing in the utility of L-Arginine in the treatment of Sickle Cell disease.

They named the team CodeBreaker. After 5 years of hard work and research validation, the CodeBreaker team went public and licensed Dr. Allen's L-Arginine Patent to a very large Global company, which hired the team to lecture globally on their breakthrough findings related to Sickle Cell and L-arginine.

The CodeBreaker team lectured all across Asia, including lectures at the *United Nations General Assembly featuring World Sickle Cell Day* in 2009, and at the Tokyo Convention Center to thousands of people, and physicians specializing in Asian Thalassemia. In Asia, Sickle Cell disease is called Thalassemia.

The CodeBreaker team was responsible for generation a \$Billion dollars in sales of Dr. Allen's L-Arginine patented Nitric Oxide formula.

This Press Release was presented and authored by:

**HOPE ALIVE - SICKLE CELL ASSOCIATION OF ABEJO KUTA,
OGUN STATE: A REGISTERED MEMBER OF THE SICKLE CELL
FOUNDATION OF NIGERIA:**

A Live Interview with Dr. Ann de Wees Allen from the United Nations General Assembly



FROM THE BLACK PREACHING NETWORK: DARWIN ALI – MEDICAL PROFESSIONALS IN THE NEWS

United Nations Interviewer: Congratulations on your presentation today to the United Nations at the *United Nations General Assembly*, regarding your research on L-Arginine and Sickle Cell, it is indeed a pleasure to speak with you.

Dr. Allen person, as I have followed your research on L-Arginine and Sickle Cell and had the pleasure of attending your scientific lectures in many of the countries in Asia when you spoke in Hong Kong, Singapore, Thailand, and Japan at the Tokyo Convention Center.

Dr. Allen: Thank you very much. It was a great honor to be invited to the *United Nations General Assembly* to present the current research on L-Arginine, Sickle Cell and other global genetic polymorphisms.

United Nations Interviewer: Your research partners from the National Institutes of Health (NIH), Johns Hopkins School of Medicine, National Human Genome Research Institute, and the National Medical Association, are here with you today at the United Nations.

Dr. Allen: Yes, we have worked for five years together on this important project, including

my dear friend and co-researcher Dr. Randall Maxey, MD, PhD, President of the National America

Quotations from Dr. Allen's research partners at the United Nations:

“Dr. Allen is a pioneer in the area of L-arginine research and began her study of the amino acid L-Arginine in 1983, years ahead of any other scientists.

Dr. Allen is solely credited with the discovery that L-Arginine is a Blind Amino Acid® and that without a Blind Amino Acid Rider®, L-Arginine can be quite dangerous in humans.

Dr. Allen's research was validated by the Journal of the American Medical Association (JAMA) and the Johns Hopkins Trial on L-Arginine. For this research, Dr. Allen received a Federal Patent.

Dr. Allen's research on L-Arginine covers Growth Hormone, Testosterone, Anti-Aging,

IGF, and nitric oxide (NO). Arginine is one of the twenty amino acids that are the building blocks of protein, and serves as the precursor to the production of nitric oxide (NO) in the body. NO circulates in the bloodstream and plays an important role in relaxation of the blood vessels, contributing to reducing blood pressure and the risk of heart disease.

Considered the leading L-Arginine researcher in the world, Dr. Allen's L-Arginine discoveries and Patents revolutionized the safe long-term use of arginine in humans.

These Patents will forever change the face of genetic polymorphisms, such as Sickle Cell in Africa and African/Americans and Thalassemia, the most widespread genetic problem in Asia."

Dr. Allen: We have worked very hard together for the past five years, and today it all became

worth it. It's astounding to stand before all of the countries represented here, and humbling.

United Nations Interviewer: In your lecture to the *Representatives of the United Nations*, you discussed methodologies for using L-Arginine in the treatment of genetic polymorphisms, including Sickle Cell and Thalassemia, particularly in children worldwide.

Is it true that you have offered to provide the use of those patents *Pro-Bono* to every country represented here at the United Nations?

Dr. Allen: Absolutely – because no scientist should own or control any important breakthrough that can help children worldwide. After 3 decades as a Clinical Researcher for the largest food companies in the world, specializing in the Glycemic Index, L-Arginine, obesity, diabetes, anti-aging, and global health, I now want to focus on bringing

future-science to the public. The best way to accomplish this goal is to align with like-minded companies.

United Nations Interviewer: Your patents and research have generated over \$ 1 Billion dollars globally and were even featured on the front page of the *Wall Street journal*. What new areas of research are you involved in now?

Dr. Allen: Scientists can lead the global force in New Science, such as Sickle Cell, Thalassemia (in Asia), Anti-Aging, and new approaches to childhood and adult obesity and diabetes. Let's face it, the standard approach to these ailments is NOT working, and we need to find solutions that get results.

The answers are within our reach, and those solutions need to be exploited and expanded for the good of human health everywhere on the globe.

United Nations Interviewer: Thanks very much Dr. Allen for the time you have spent with me today.

END DOCUMENT: DR ALLEN BIO-422: DEC 2024

UNITED NATIONS GENERAL ASSEMBLY

PAGE 27 of 27

COPYRIGHT® 2009